STAFF BOARD
Article
CHAIRMAN
Manuela Velázquez Prieto
EDITOR IN CHIEF
Jaime E. Poquet Jornet
MARKETING MANAGER
EDITORIAL BOARD
Tomás Casasín Edo
Virginia Hernández Corredoira
Ramón Jódar Masanés
Juan Carlos Juárez Giménez
Volume 20 - Issue 1, January-February 2018
SHORT REPORTS
USE OF ENOXAPARIN IN PATIENTS WITH CHRONIC RENAL IMPAIRMENT: IT IS NOT CLEAR AFTER 25 YEARS OF ITS APPROVAL
GALLEGO MUÑOZ CRISTÓBAL, CABALLERO REQUEJO MARÍA DEL CARMEN, ONTENIENTE CANDELA MARÍA, GIL CANDEL MAITE


The European Medicines Agency approved enoxaparin, a low-molecular-weight heparin, in 1989. Despite the benefits seen in using enoxaparin rather than unfractionated heparin in treating vein thrombosis and pulmonary embolism, enoxaparin’s relatively high degree of renal excretion raises a concern for drug accumulation and a commensurate increased bleeding risk in patients with renal impairment. These pharmacokinetic properties led to an European Medicines Agencyapproved two-tiered dosing strategy with a CrCl cutoff of 30 ml/min; however,
both pharmacokinetic and outcomes data seem to demonstrate that enoxaparin could be used even more effectively and safely with a multitiered enoxaparin renal dosing strategy. Lower doses should be used for populations in the 30 ml/min to 50 or 60 ml/min CrCl range and in the less than more definitively refine renal
dosing guidelines beyond what is currently by the European Medicines Agency. Larger controlled trials are needed to definitively establish the role and methods of using enoxaparin for vein thrombosis and pulmonary embolism with further dose adjustments in patients with varying degrees of renal impairment.

BLEEDING – ENOXAPARIN – LOW-MOLECULAR-WEIGHT HEPARIN –
PHARMACOKINETICS – RENAL IMPAIRMENT



Fill out the form below to buy this article

Name and surname:

DNI/NIF ID/VAT IDENTIFICATION No.:

Contact Email:

Phone:

Address:

Zip code:

City:

Province:

Country:

*I have read and accept the privacy policy
Price : 30,25